MARK REGINATO: Open Payments
NPI 1194884502 · DANVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,389 in 161 payments from 49 companies in 2025. Trend: 2023 $3,241 · 2024 $3,319 · 2025 $3,389
Food & beverage: $3,389
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $348 |
| PFIZER INC. | 10 | $217 |
| Amgen Inc. | 9 | $168 |
| Novo Nordisk Inc | 6 | $155 |
| AstraZeneca Pharmaceuticals LP | 7 | $151 |
| GlaxoSmithKline, LLC. | 6 | $135 |
| Exact Sciences Corporation | 5 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $126 |
| Esperion Therapeutics, Inc. | 6 | $117 |
| Axsome Therapeutics, Inc. | 4 | $116 |
Products named: REXULTI, OTEZLA, UBRELVY, CAPLYTA, NEXLETOL, Auvelity, XIFAXAN, Cologuard Collection Kit.
Industry payments across CA — which companies pay providers there.
